The enzyme 2', 5'-oligoadenylate synthetase (2', 5'-A synthetase) is induced by interferons as an essential step in limiting virus growth.' 2 Raised 2', 5'-A synthetase concentrations have been detected in blood lymphocytes of patients with several virus infections and autoimmune diseases, 3 although it now appears that there is some increase in enzyme concentration in patients with bacterial infections.4
These observations complement the many reports of interferon-like activity in the serum of patients with SLE,s though studies of this kind have given conflicting results. 6 The subject is important for two reasons. Firstly 4.
group (Fig. 1) . Accordingly the results were analysed after five and 22 hours of culture. Basal concentrations of 2', 5'-A synthetase in normal lymphocytes were low (Fig. 2) . In contrast, high levels of spontaneous activity were found in SLE patients. Increased enzyme concentrations were also present in lymphocytes from patients with Behcet's syndrome and rheumatoid arthritis. However, these were less pronounced and similar increases were observed in lymphocytes from control patients in other diseases (Table 1 ). There was no correlation between enzyme concentration and disease features or activity in any of these patient groups. Nor did drug treatment influence the results.
INDUCTION OF LYMPHOCYTE 2', 5'-A SYNTHETASE BY IFN-a
The amount of 2', 5'-A synthetase induced by IFN-a was dose dependent and time dependent (Fig. 1) . 500 U IFN-a was used as the standard inducing dose, and enzyme activity was measured five and 22 hours after stimulation.
IFN-a induced enzyme activity in lymphocytes of all patient groups which was detectable after five hours (Fig. 3a) and 22 hours (Fig. 3b) Given the wide range of disorders associated with increased enzyme concentrations in blood lymphocytes, these observations do not help to define possible aetiological agents in connective tissue disease. Furthermore, since there are numerous pathways by which immune responses induce interferon production, enzyme induction could simply reflect the characteristic immunoproliferative events in these diseases, irrespective of their cause. Nevertheless, our results show that enzyme induction in diseases such as SLE is more likely to reflect prolonged exposure to interferons than other mechanisms associated with lymphocyte activation; PHA, though a potent non-specific lymphocyte activator, induced little enzyme activity in cells from any of the disease groups. Thus induction of 2', 5'-A synthetase in lymphocytes is a potential means of screening putatively infected cells for low levels of interferon release.
Minor differences were observed in the ability of IFN-a to induce enzyme in lymphocytes from patients with different diseases. However, this may reflect the extent to which the blood concentration of responsive lymphocytes is affected by these diseases. Moreover, since the enzyme concentration in unstimulated cells also varied, impoverished responses to in vitro challenge with IFN-a may be explained by their relative refractoriness to further stimulation. Defective lymphocyte production of interferons has been reported in SLE,'2 and there has been considerable speculation about possible defects in the ability of different mononuclear populations in this disease to produce or respond to interferons. Since SLE lymphocytes produce 2', 5'-A synthetase both spontaneously and in response to IFN-a, it is unlikely that there are gross defects of this kind. 
